ArticlebioRxiv : the preprint server for biology2026
PXN Unlocks the Power of Public Gene Expression Data Through Cross-Technology Integration.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The immense value of public gene expression repositories is constrained by the lack of compatibility among datasets generated from diverse experimental technologies. Differences in measurement scales, probe chemistries, and signal distributions create systematic discrepancies across platforms and laboratories. These inconsistencies make large-scale integrative analysis nearly impossible, even though such studies could achieve great statistical power and improved reproducibility. We introduce PXN, a probabilistic machine learning framework that captures a unified representation of biological signal across multiple gene expression technologies. Once trained, PXN can seamlessly translate data between multiple platforms, preserving informative biological variation while removing technology-specific biases. In benchmarking studies, PXN consistently outperforms existing normalization methods in cross-platform accuracy and substantially enhances the power of differential expression analysis. Importantly, we show that PXN is powerful enough to bridge even the most challenging technological divide-between microarray and RNA-seq. This capability provides a scalable route for integrating legacy microarray data with modern RNA-seq studies. By enabling direct comparison and integration of heterogeneous datasets, PXN unlocks the full potential of public repositories for future biological discovery and therapeutic innovation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.